New Harbor Capital Portfolio Company LGM Pharma Promotes CFO and CCO
New Harbor Capital (“New Harbor”) is excited to announce that portfolio company LGM Pharma (“LGM”, “the Company”) has promoted Richard Goitia to Chief Financial Officer and Hamilton Lenox to Chief Commercial Officer.
LGM Pharma is a provider of comprehensive API sourcing and drug product contract development and manufacturing (“CDMO”) solutions to the pharmaceutical, biotechnology, and compounding pharmacy end markets. LGM assists clients in managing all phases of the drug product development process, from API sourcing through to commercialization. The Company’s extensive global network of qualified API partners enable clients to optimize supply chain management and distribution.
“New Harbor is very excited to announce the promotions of Richard and Hamilton,” said Jocelyn Stanley, Partner at New Harbor Capital. “Richard’s tenured financial leadership experience and Hamilton’s deep pharmaceutical industry expertise have been instrumental to LGM’s growth. We look forward to their continued contributions to the Company’s success.”
“We are thrilled to promote Richard and Hamilton to these leadership roles at LGM,” said Dr. Prasad Raje, CEO of LGM Pharma. “In just five years, they have helped LGM evolve from a small, 33-person supply chain business into a global organization with over 235 employees and multiple U.S. manufacturing sites. This significant growth is a testament to their dedication and the hard work of their teams.”
Richard Goitia, Chief Financial Officer, LGM Pharma
Richard Goitia brings over two decades of financial and accounting expertise to his role as Chief Financial Officer of LGM Pharma. With a background in industries such as real estate and telecommunications, Richard joined LGM in 2019 as the Vice President of Finance and Accounting. His strategic leadership has been crucial to LGM’s growth. Under Richard’s guidance, the Company has implemented robust financial systems and processes and expanded its human resources capabilities, including transitioning to ADP and expanding the Company’s 401k program.
Hamilton Lenox, Chief Commercial Officer, LGM Pharma
Hamilton Lenox brings over 20 years of pharmaceutical experience to his role as Chief Commercial Officer of LGM Pharma. With a specialization in API and CDMO services, Hamilton joined LGM in 2018 and has since played a pivotal role in the company’s growth and expansion. Under Hamilton’s leadership, LGM has established numerous essential processes, such as the implementation of both Salesforce CRM and SAP to drive growth across the Supply Chain and CDMO divisions.
About LGM Pharma
LGM Pharma is a contract development and manufacturing organization (CDMO) providing comprehensive Active Pharmaceutical Ingredient (API) sourcing and drug product CDMO solutions to the pharmaceutical, biotechnology, and compounding pharmacy industries. LGM Pharma assists clients in managing all phases of the drug product development process, from API sourcing through to commercialization. LGM Pharma’s extensive global network of qualified API partners enable clients to optimize supply chain management and distribution. Services include API sourcing and procurement, formulation development, analytical method development, method and process validation, ANDA/NDA submission, stability studies, and raw material and finished product testing and packaging. LGM Pharma is committed to quality and has a track record of providing expert regulatory and market intelligence services to its clients. The company is focused on customer service and customized solutions, providing clients with a comprehensive one-stop manufacturing solution that reduces risk, increases efficiency, and accelerates the path to commercialization. For more information, visit www.lgmpharma.com.